A study of TY-9591 for lung cancer that has spread to the brain
Original title: TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so it is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called TY-9591 in people whose lung cancer has spread to the brain.
Who this trial is for. This trial is for people with non-small cell lung cancer that has a gene change called EGFR, and whose cancer has spread to the brain. It tests TY-9591 as the first treatment and compares it with a drug called Osimertinib.
Where it stands. The trial has not reported results. It is looking at how well TY-9591 works and how safe it is. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, you could ask your care team about it. They can help you learn if a trial like this is a fit for you.
What it doesn't mean: This does not mean TY-9591 is a proven treatment. A trial is a test. Being in one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.